It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dynamin-like GTPase proteins, including myxoma (Mx) and guanylate-binding proteins (GBPs), are among the many interferon stimulated genes induced following viral infections. While studies report that human (h)GBPs inhibit different viruses in vitro, few have convincingly demonstrated that mouse (m)GBPs mediate antiviral activity, although mGBP-deficient mice have been used extensively to define their importance in immunity to diverse intracellular bacteria and protozoa. Herein, we demonstrate that individual (overexpression) or collective (knockout (KO) mice) mGBPs of the chromosome 3 cluster (mGBPchr3) do not inhibit replication of five viruses from different virus families in vitro, nor do we observe differences in virus titres recovered from wild type versus mGBPchr3 KO mice after infection with three of these viruses (influenza A virus, herpes simplex virus type 1 or lymphocytic choriomeningitis virus). These data indicate that mGBPchr3 do not appear to be a major component of cell-intrinsic antiviral immunity against the diverse viruses tested in our studies.
Mouse guanylate binding proteins of the chromosome 3 cluster (mGBPchr3) do not mediate potent antiviral activity against different human or mouse viruses in vitro and in vivo.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); at The Peter Doherty Institute for Infection and Immunity, WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Victoria, Australia (GRID:grid.433799.3) (ISNI:0000 0004 0637 4986)
2 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889)
3 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); University of Technology Sydney, School of Life Sciences, Faculty of Science, Ultimo, Australia (GRID:grid.117476.2) (ISNI:0000 0004 1936 7611)
4 University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
5 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
6 Osaka University, Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)